Evaluate Severe Hepatic Impairment on Dacomitinib PK

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

October 24, 2019

Study Completion Date

October 24, 2019

Conditions

Severe Hepatic Impairment

Interventions

DRUG

Dacomitinib

anti-cancer agent

Trial Locations (3)

Orlando Clinical Research Center, Orlando

Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami

University of Miami Division of Clinical Pharmacology, Miami